CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection

• Published in: Expert opinion on drug metabolism & toxicology Vol. 6; no. 1; p. 29
• Main Authors: Yang, Jyh-Chin, Lin, Chun-Jung
• Format: Journal Article
• Language: English
• Published: England 01.01.2010
• Subjects: Aryl Hydrocarbon Hydroxylases - genetics; Aryl Hydrocarbon Hydroxylases - metabolism; Cytochrome P-450 CYP2C19; Genotype; Helicobacter Infections - drug therapy; Helicobacter Infections - microbiology; Helicobacter pylori; Humans; Proton Pump Inhibitors - pharmacokinetics; Proton Pump Inhibitors - pharmacology; Proton Pump Inhibitors - therapeutic use
• ISSN: 1744-7607
• DOI: 10.1517/17425250903386251

Proton pump inhibitors (PPIs) are potent gastric acid inhibitors. Therapies with a PPI and antibiotics are used to cure Helicobacter pylori (H. pylori) infection, which is closely related to many gastrointestinal diseases. Most PPIs are mainly metabolized by cytochrome 2C19 (CYP2C19). The genetic polymorphisms of CYP2C19 may lead to the differences in pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of PPIs. The roles of PPIs on the eradication of H. pylori are summarized. The impact f CYP2C19 polymorphism on the PK and PD of PPIs is addressed and related to the present status of therapy for H. pylori infection. The opinions on the strategy of PPIs-based therapies of H. pylori infection are provided. Update the factors that may influence the PPIs-based therapies of H. pylori infection. The eradication rates of H. pylori infection are significantly different between patients who are CYP2C19 extensive metabolizers and poor metabolizers, partly because of the differences in the PK and PD of PPIs. Nonetheless, the differences can be improved by adjusting the regimens of PPIs and using antibiotics that have less H. pylori-resistance.